Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype

Thrombosis and Haemostasis

Volumn 91, Issue 1, 2004, Pages 95-101

  Van Dijk, Karen N ^a,b   Plat, Arian W ^a   Van Dijk, Alieke A C ^a   Piersma Wichers, Margriet ^c   De Vries Bots, Anne M B ^d   Slomp, Jennita ^e   De Jong Van Den Berg, Lolkje T W ^a   Brouwers, Jacobus R B J ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

^c Thrombosis Service Groningen   (Netherlands)

^d Pharmacy't Hooge Zand   (Netherlands)

^e Department of Clinical Chemistry   (Netherlands)

Author keywords

Acenocoumarol; CYP2C9; Drug interaction; NSAIDs

Indexed keywords

ACENOCOUMAROL; COUMARIN; CYTOCHROME P450 2C9; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

AGE; ALLELE; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REGIMEN; ELDERLY CARE; FEMALE; GENDER; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; THROMBOSIS;

EID: 1642475072     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-05-0325     Document Type: Article

References (35)

1. Hirsch J. Oral anticoagulant drugs. New Engl J Med 1991; 324: 1865-75.
2. Van Der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993; 153: 1557-62.
3. Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996; 30: 416-44.
4. Brouwers JRBJ, De Smet PAGM. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1994; 27: 462-85.
5. Commissie Interacterende Medicatie Cumarines. Standard Afhandeling Cumarine-Interacties (in Dutch). Wetenschappelijk Instituut Nederlandse Apothekers (WINAp). The Hague, The Netherlands, 1999
6. Breukink-Engbers WG. Monitoring therapy with anticoagulants in the Netherlands. Semin Tromb Hemost 1999; 25: 37-42.
7. Philips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA 2001; 286: 2270-9.
8. Roland Wolf C, Smith G, Smith RL. Pharmacogenetics. BMJ 2000; 320: 987-90.
9. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667-71.
10. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28: 1284-90.
11. Klose TS, Ibaenu GC, Ghanayem BI, et al. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. Arch Biochem Biophys 1998; 357: 420-8.
12. Bliesath H, Huber R, Steinijans VW, Koch HJ, Wurst W, Mascher H. Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Int J Clin Pharmacol Ther 1996; 34 (suppl 1): S76-S80.
13. Leemann T, Transon C, Dayer P. Cytochrome P450 TB (2C9): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 1993; 52: 29-34.
14. Miners JO, Coulter D, Tukey RH, et al. Cytochromes P450, 1A2 and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem Pharmacol 1996; 51: 1003-8.
15. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathological conditions. Clin Pharmacol Ther 1997; 61: 331-9.
16. Trombotest. In: Van Leusden HAIM, ed. Diagnostisch Kompas. The Netherlands: College voor Zorgverzekeringen, 2003: 769-70.
17. Wang S-L, Huang J-D, Lai M-D, et al. Detection of CYP2C9 polymorphism based on polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5: 37-42.
18. Steward D, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7: 361-7.
19. Hylek EM, Chang YC, Skates SJ, et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000; 160: 1612-7.
20. Tassies D, Freire D, Pijoan J, et al. Pharmacogenetics of acenocoumarol: Cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematology 2002; 87: 1185-91.
21. Thijssen HHW, Verkooyen IWC, Frank HLL. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics 2000; 10: 1-4.
22. Van Der Heijden JF, Schmits S, Remkes MGH, et al. CYP2C9 Polymorphisms impair acenocoumarol metabolism, but do not increase bleeding risk. Blood 2002; 100: 149a.
23. Hermida J, Zarza J, Alberca I, et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 2002; 99: 4237-9.
24. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-19.
25. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
26. Knijff-Dutmer EAJ, Schut GA, Van De Laar AFJ. Concomitant coumarin-NSAID therapy and risk for bleeding. Ann Pharmacother 2003; 37: 12-6.
27. Bonnabry P, Desmeules J, Rudaz S, et al. Stereoselective interaction between piroxicam and acenocoumarol. Br J Clin Pharmacol 1996; 41: 525-30.
28. Pardo A, Garcia-Losa M, Fernandez-Pavon A, et al. A placebo-controlled study of interaction between nabumetone and acenocoumarol. Br J Clin Pharmacol 1999; 47: 441-4.
29. Masche UP, Rentsch KM, Von Felten A, et al. No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics. Eur J Clin Pharmacol 1999; 54: 865-8.
30. Chan TY. Prolongation of prothrombin time with the use of indomethacin and warfarin. Br J Clin Pract 1997; 51: 177-8.
31. Karim A, Tolber D, Piergies A, et al. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. J Clin Pharmacol 2000; 40: 655-63.
32. Haasse KK, Rojas-Fernandez CH, Lane L, et al. Potential interaction between celecoxib and warfarin (letter). Ann Pharmacother 2000; 34: 666-7.
33. Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. Ann Pharmacother 2000; 34: 325-7.
34. Stading JA, Skrabal MZ, Faulkner MA. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health-Syst Pharm 2001; 58: 2076-80.
35. Schaefer MG, Plowman BK, Morreale AP, et al. Interaction of rofecoxib and celecoxib with warfarin. Am J Health-Syst Pharm 2003; 60: 1319-23.